Congenital Disorder of Glycosylation Type 1h

Congenital disorder of glycosylation type 1h (CDG-Ih, also called ALG8-CDG) is a rare, inherited condition that affects the way the body adds sugar chains to proteins. This sugar-adding process is called N-glycosylation. In CDG-Ih, changes (variants) in the ALG8 gene stop an enzyme in the cell’s “factory” (the endoplasmic reticulum) from adding the second glucose to a growing sugar chain. Because of this early building error, many proteins all over the body are not made correctly. When proteins are under-glycosylated, many organs can be affected—brain, gut, liver, blood, eyes, heart, skin, and muscles. Babies usually show signs in infancy. There is no disease-specific cure yet; care focuses on treating symptoms, protecting nutrition, and preventing complications. CDG Hub+3PubMed+3PMC+3

CDG-Ih is a rare, inherited metabolic disease that starts before birth. It affects how the body builds sugar chains (called N-glycans) and attaches them to proteins. These sugar chains help proteins fold, travel, and work in many organs. In CDG-Ih, a gene named ALG8 does not work properly. ALG8 normally adds a glucose (a sugar) to a growing sugar chain on a lipid “carrier” inside the endoplasmic reticulum (ER). When ALG8 is not working, the sugar chain is built incorrectly. As a result, many proteins are under-glycosylated (they do not get enough sugar chains). This disrupts many body systems at once, including the brain, liver, gut, eyes, muscles, and blood-clotting system. Orpha.net+2BioMed Central+2

Because many organ systems need glycosylated proteins to function, babies with CDG-Ih often show problems soon after birth. Typical features can include feeding difficulty, failure to gain weight, swelling (edema), low muscle tone, developmental delays, seizures, liver disease, blood-clotting problems, and sometimes eye and skeletal changes. Orpha.net+2Genetic Diseases Info Center+2

Other names

• ALG8-CDG

• Congenital disorder of glycosylation due to ALG8 deficiency

• CDG type Ih / CDG-Ih

• Glucosyltransferase I deficiency (describes the blocked step in the glycosylation pathway) Orpha.net

(You might also see “carbohydrate-deficient glycoprotein syndrome” in older literature. That was the earlier umbrella name for CDG conditions). NCBI

How CDG-Ih works

Inside cells, N-glycans are built step-by-step on a lipid called dolichol. ALG8 is one of the “assembly-line” enzymes that adds a glucose unit during this build. If ALG8 is missing or weak, the chain is incomplete. The incomplete chain cannot be attached properly to proteins, so many proteins reach their destination without the sugar “tags” they need. This can disturb cell signaling, hormone transport, clotting factors, digestive proteins, and membrane proteins in nerves and muscles. Clinically, this shows up as a “type I” transferrin pattern on screening (explained below), because the failure happens during the assembly or transfer stage of N-glycans. ScienceDirect+2Frontiers+2

Types

CDG-Ih is one genetic disease, but doctors sometimes describe forms based on how and when it presents:

1. Prenatal/Perinatal form – Signs may appear before birth, such as generalized swelling (hydrops fetalis) or severe edema. After birth, there may be feeding issues, low tone, and failure to thrive. Orpha.net

2. Infantile multisystem form (classic) – Most cases start in the newborn period or infancy with feeding problems, diarrhea, protein-losing enteropathy (loss of protein into the gut causing swelling and low albumin), liver enlargement, low muscle tone, developmental delay, seizures, and blood-clotting problems. Some infants develop cataracts or foot deformities (clubfoot). This form can be severe. BioMed Central+1

3. Childhood form with neurodevelopmental features – Some children live beyond infancy but have varied degrees of intellectual disability, motor delay or ataxia, and sometimes autism spectrum or behavioral features. The severity is broad, and some features can be stable over time. PMC

4. Related condition in carriers – People with one faulty ALG8 copy (heterozygous carriers) usually do not have CDG-Ih, but some heterozygous variants have been linked to autosomal dominant polycystic liver disease as a separate condition. This is different from CDG-Ih, which requires two faulty copies (autosomal recessive). GeneCards

Causes and risk factors

Remember: the root cause is pathogenic variants in both copies of the ALG8 gene (autosomal recessive inheritance). The list below breaks this core cause into practical, biological, and clinical “sub-causes” or risk contexts that explain why disease happens and how it varies:

1. Pathogenic ALG8 variants (loss of function) – Nonsense, frameshift, splice, or severe missense changes can inactivate the enzyme, blocking the glucose-adding step. Orpha.net

2. Hypomorphic missense variants – Some missense changes partially reduce function, which can modulate severity but still cause disease if both copies are affected. BioMed Central

3. Compound heterozygosity – Two different harmful variants (one on each copy) combine to cause disease. BioMed Central

4. Autosomal recessive inheritance – Parents are usually healthy carriers; each child has a 25% chance to be affected. (Inheritance pattern across CDG-Ih families.) BioMed Central

5. Consanguinity – When parents are related, the chance of both passing on the same rare variant rises. (Observed in some severe cases of CDG subtypes.) ScienceDirect

6. ER quality-control stress – Mis-glycosylated proteins misfold more easily, straining the ER’s folding machinery (calnexin/calreticulin cycle) and lowering protein function. (Mechanism common to type I CDGs.) Frontiers

7. Defective lipid-linked oligosaccharide (LLO) assembly – The N-glycan “scaffold” is incomplete; fewer proteins get glycosylated. (Defines type I CDGs.) ScienceDirect

8. Reduced secretion of glycoproteins – Hormones, enzymes, and transport proteins may not be properly processed or secreted. (General CDG effect.) Frontiers

9. Coagulation factor hypoglycosylation – Several clotting factors are glycoproteins; low glycosylation impairs clotting and can cause bleeding or abnormal labs. Orpha.net

10. Protein-losing enteropathy triggers – Fragile gut barrier and lymphatic flow changes may worsen protein loss into the intestine, lowering albumin and causing edema. BioMed Central

11. Hepatocellular stress – The liver depends heavily on glycoprotein processing; under-glycosylation promotes hepatomegaly and liver dysfunction. Orpha.net

12. Neurological vulnerability – Developing brain circuits require many membrane and adhesion glycoproteins; faulty glycosylation impairs synaptic function and myelination. (General CDG concept.) Frontiers

13. Ocular tissue sensitivity – The lens and retina rely on healthy protein turnover; under-glycosylation contributes to cataract and retinal degeneration in some patients. Frontiers in Glycosylation

14. Skeletal/soft tissue development effects – Connective tissue and cartilage glycoproteins help joint stability; their impairment can lead to clubfoot and joint laxity. Frontiers in Glycosylation

15. Cardiac rhythm susceptibility – Glycosylation affects ion channels and conduction proteins; arrhythmias or structural heart issues may appear. Frontiers in Glycosylation

16. Immune/hematologic effects – Several immune proteins and complement components are glycoproteins; under-glycosylation can contribute to infection or inflammatory issues. (General CDG principle.) Frontiers

17. Nutritional stressors – Illness, fasting, or poor intake can worsen failure to thrive because the body already handles proteins inefficiently. (Clinical observation across CDGs.) CDG Hub

18. Intercurrent infections – Fevers and infections may unmask or aggravate weakness, seizures, or edema in infants with fragile metabolic balance. (General CDG care reality.) CDG Hub

19. Genetic background modifiers – Other genes can slightly change severity even with the same ALG8 variants, explaining variability between patients. (Noted across CDGs.) Frontiers

20. Late or missed diagnosis – Delays in recognizing CDG can allow complications such as severe malnutrition or clotting events to progress. Early biochemical and genetic testing helps. Frontiers+1

Common symptoms and signs

1. Poor feeding and vomiting – Babies struggle to feed, often spit up or vomit, and may not keep food down. This leads to poor weight gain and low energy. Orpha.net

2. Failure to thrive – Despite feeding efforts, weight and length fall off the growth curve because nutrients are not absorbed or used efficiently. Orpha.net

3. Protein-losing enteropathy with edema – Protein leaks into the gut. Blood protein (albumin) drops. Fluid collects in tissues and body cavities, causing swelling or ascites; severe cases may show hydrops fetalis before birth. BioMed Central

4. Low muscle tone (hypotonia) – The baby feels “floppy,” delays head control, and later has delayed motor milestones. Orpha.net

5. Developmental delay – Learning and motor skills are behind schedule; speech and coordination may also be affected. Orpha.net

6. Seizures – Abnormal electrical activity in the brain can cause seizures; EEG often shows abnormalities. Orpha.net

7. Ataxia or coordination problems – Some children have unsteady movements due to impaired cerebellar or sensory pathways. Orpha.net

8. Liver enlargement and dysfunction – The liver may be big (hepatomegaly), and liver blood tests can be abnormal. Orpha.net

9. Clotting problems – Easy bruising or abnormal coagulation tests can occur because clotting factors are glycoproteins and are under-glycosylated. Orpha.net

10. Kidney tubule issues – Some patients have renal tubulopathy, which can disturb salt and acid-base balance. Orpha.net

11. Eye problems – Cataracts, retinal degeneration (retinitis pigmentosa), and strabismus (crossed eyes) may develop in infancy or childhood. Frontiers in Glycosylation

12. Dysmorphic features – Some babies have low-set ears, small jaw (retrognathia), and other subtle facial differences. Orpha.net

13. Skeletal findings – Clubfoot (equinovarus), joint laxity or subluxation, and short fingers (brachydactyly) have been reported. Frontiers in Glycosylation

14. Skin changes – Pale skin and increased skin wrinkling can appear. Frontiers in Glycosylation

15. Heart issues – Some individuals have structural heart changes or arrhythmias that need monitoring. Frontiers in Glycosylation

(Doctors have also reported stable intellectual disability and autism-spectrum or behavioral features in some children with ALG8-CDG.) PMC

Diagnostic tests

Below are tests that doctors use to suspect, support, and confirm CDG-Ih. Not every patient needs every test. The mix depends on symptoms and local resources.

A) Physical examination (bedside assessments)

1. Growth and nutrition check – Weight, length, head size, and feeding history. The pattern of poor growth with feeding problems and edema raises suspicion for a multisystem disorder like CDG. Orpha.net

2. Neurologic exam – Tone (often low), reflexes, coordination, eye movements, and seizures are assessed to define the neurodevelopmental profile. Orpha.net

3. Abdominal exam – Doctors feel for hepatomegaly, splenomegaly, or ascites (fluid), which are common in severe infantile presentations. Orpha.net

4. Eye exam at the bedside – A red reflex test and basic ocular inspection may suggest cataract or strabismus; this prompts full ophthalmology referral. Frontiers in Glycosylation

5. Cardiorespiratory exam – Heart rate and rhythm assessment may reveal arrhythmia; heart findings guide further cardiac testing. Frontiers in Glycosylation

B) Manual/functional tests (structured clinical evaluations)

6. Feeding and swallow evaluation – Speech-language or feeding therapists assess suck-swallow-breathe coordination and aspiration risk; guides nutrition plans. (Common in CDG infants with severe feeding difficulty.) Orpha.net

7. Developmental screening tools – Standard scales (e.g., Bayley) quantify delays and help track progress and therapy response over time. (General CDG care.) CDG Hub

8. Tone and posture assessments – Physical therapy uses simple maneuvers to measure hypotonia and core stability, shaping early intervention. (General CDG care.) CDG Hub

9. Ataxia/coordination bedside tests – Finger-to-nose, heel-to-shin, and gait observation define motor control and fall risk. (General for CDG with ataxia.) Orpha.net

10. Ophthalmology slit-lamp and fundus exam – Confirms cataract or retinal degeneration; directs timing of surgery or vision support. Frontiers in Glycosylation

C) Laboratory and pathological tests

11. Serum transferrin isoform analysis – Transferrin isoelectric focusing (IEF) or capillary electrophoresis screens for CDG. Type I pattern suggests a defect in glycan assembly/transfer, which fits ALG8-CDG; it’s the classic first-line biochemical screen. Frontiers+2Heft Pathology+2

12. Mass spectrometry glycomics / HPLC – Advanced glycan profiling can support and refine the biochemical diagnosis when available. Frontiers

13. Apolipoprotein C-III analysis – Used mainly when a type II pattern is suspected; part of the overall CDG algorithm to separate assembly defects (type I) from processing defects (type II). CDG Hub

14. Genetic testing of ALG8 – Definitive diagnosis. Sequencing (single-gene, gene panels, or exome/genome) identifies pathogenic variants in both ALG8 copies. CDG Hub

15. Liver function and protein panel – AST/ALT, bilirubin, albumin, and total protein assess liver involvement and protein-losing enteropathy. Orpha.net

16. Coagulation studies – PT/INR, aPTT, fibrinogen, antithrombin, protein C/S help detect hypoglycosylation-related coagulopathy seen in several CDGs. Orpha.net

17. Stool alpha-1 antitrypsin – Measures protein loss into the intestine; supports the diagnosis of protein-losing enteropathy when edema and low albumin are present. (Used in practice for PLE.) Mayo Clinic Laboratories

18. Cell-based LLO analysis – Specialized labs can analyze lipid-linked oligosaccharides in fibroblasts to confirm a type I assembly problem consistent with ALG8 deficiency. CDG Hub

D) Electrodiagnostic tests

19. EEG (electroencephalogram) – Detects seizure activity and guides anti-seizure treatment. Seizures are common in infantile CDG-Ih. Orpha.net

20. Nerve conduction/EMG (select cases) – If neuropathy or significant hypotonia raises concern, these tests help define nerve/muscle involvement. (Used across CDGs when indicated.) Frontiers

(Additional monitoring that is often used: ECG for rhythm screening and echocardiogram for structure/function if heart concerns arise.) Frontiers in Glycosylation

E) Imaging tests

1. Brain MRI – Looks for structural changes that may explain seizures or motor findings; patterns vary across CDGs. (Used based on clinical need.) Frontiers

2. Abdominal ultrasound – Checks for hepatomegaly, ascites, and other abdominal findings; also monitors nutrition complications. Orpha.net

3. Echocardiogram – Evaluates heart structure and function when murmurs, arrhythmias, or poor perfusion are suspected. Frontiers in Glycosylation

4. Ophthalmic imaging (as needed) – Optical coherence tomography (OCT) or retinal photos help document retinal degeneration and guide low-vision care. Frontiers in Glycosylation

5. Prenatal ultrasound – May detect hydrops or edema, which can prompt early metabolic evaluation after birth. Orpha.net

Non-pharmacological treatments (therapies & others)

These measures are the backbone of care because there is no ALG8-specific drug therapy yet. Management is individualized by a multidisciplinary team. CDG Hub+1

1. High-protein nutrition plan
   Purpose: restore serum proteins and support growth.
   Mechanism: more dietary amino acids to replace losses from PLE. Dietitian monitors calories and micronutrients. UVA School of Medicine

2. Medium-chain triglyceride (MCT) enrichment
   Purpose: improve fat absorption when intestinal lymph loss is suspected.
   Mechanism: MCTs bypass lymphatics and are absorbed directly into the portal vein. UVA School of Medicine

3. Salt and fluid management
   Purpose: reduce edema while maintaining hydration.
   Mechanism: careful sodium moderation plus guided fluids/ORS decrease swelling but prevent dehydration. UVA School of Medicine

4. Physiotherapy
   Purpose: improve tone, posture, motor skills.
   Mechanism: repetitive, goal-directed movement builds strength and motor control in hypotonia. CDG Hub

5. Occupational therapy
   Purpose: daily living skills, fine motor function, adaptive equipment.
   Mechanism: task-specific training and environmental adaptation.

6. Speech and feeding therapy
   Purpose: safe swallowing, feeding efficiency, communication.
   Mechanism: oromotor training; texture modification; augmentative communication as needed. CDG Hub

7. Ketogenic diet for difficult seizures (specialist-guided only)
   Purpose: seizure control when medications fail.
   Mechanism: ketosis alters brain metabolism and neuronal excitability; used in CDGs including ALG3-CDG and reported across CDG cohorts. PMC+1

8. Vision therapy & early ophthalmology care
   Purpose: optimize visual development, manage strabismus/amblyopia.
   Mechanism: early correction (patching, lenses) supports neural visual pathways. PubMed

9. Orthopedics/orthotics (Ponseti casting for clubfoot)
   Purpose: align feet to enable standing/walking.
   Mechanism: serial manipulation/casting with Achilles tenotomy if needed. Hospital for Special Surgery+1

10. Developmental and behavioral therapy
    Purpose: support learning and behavioral needs, including autism features.
    Mechanism: structured early intervention, ABA/OT/SLP as appropriate. PMC

11. Skin and lymphedema care
    Purpose: protect fragile, swollen skin.
    Mechanism: compression garments, emollients, infection prevention.

12. Immunization optimization
    Purpose: reduce infection risk.
    Mechanism: on-time vaccines; consider RSV prevention if indicated. (General pediatric guidance in chronic disease.)

13. Gastrostomy tube feeding (when needed)
    Purpose: secure calories, reduce aspiration.
    Mechanism: direct gastric feeds with careful formula selection (often MCT-inclusive).

14. Palliative and supportive care
    Purpose: symptom relief, family support, goals-of-care planning.
    Mechanism: expert management of complex symptoms.

15. Genetic counseling
    Purpose: explain inheritance (autosomal recessive), recurrence risk, and testing options for family.
    Mechanism: targeted family testing and reproductive planning. CDG Hub

16. Peri-procedure hemostasis planning
    Purpose: reduce bleeding/clot events around surgeries.
    Mechanism: pre-op labs and individualized factor/AT plans. Wiley Online Library

17. Infection-prevention habits at home
    Purpose: fewer illnesses with PLE.
    Mechanism: hand hygiene, prompt care for fever/diarrhea.

18. Vitamin/trace-element repletion plan
    Purpose: prevent deficiencies (A, D, E, K, zinc, iron, folate/B12).
    Mechanism: targeted supplementation based on labs. UVA School of Medicine

19. Care coordination across specialists
    Purpose: reduce missed issues and duplicative care.
    Mechanism: shared care plan (metabolic, GI, liver, heme, neuro, cardio, eye, ortho).

20. Community and research registry engagement
    Purpose: access to trials and family support.
    Mechanism: connect with CDG networks (e.g., CDG Hub, CDG CARE). Frontiers

---

Drug treatments

Important safety note: Doses for infants and children are highly individualized and must be prescribed by the treating specialists. The examples below show typical clinical uses with brief mechanisms; they are not personal medical advice.

1. Levetiracetam (antiepileptic)
   Purpose: control seizures. Mechanism: binds SV2A to reduce synaptic neurotransmitter release. Often used first-line in CDG cohorts. Side effects: irritability, somnolence. HSSiEM

2. Clonazepam (antiepileptic/benzodiazepine)
   Purpose: adjunct for seizures or myoclonus. Mechanism: enhances GABAergic inhibition. Side effects: drowsiness, dependence risk. HSSiEM

3. Lamotrigine (antiepileptic)
   Purpose: adjunct in focal/generalized seizures. Mechanism: sodium-channel modulation; glutamate release inhibition. Side effects: rash (seek urgent care if severe). HSSiEM

4. Ketogenic diet (listed above as non-pharm; noted here to reflect antiepileptic role). Mechanism: metabolic shift reduces neuronal excitability; used when drugs insufficient. PMC

5. Budesonide (enteric corticosteroid)
   Purpose: reduce PLE-related gut inflammation/lymphangiectasia in selected cases (extrapolated evidence). Mechanism: local steroid effect in intestine. Side effects: cushingoid features, growth effects with long use. Medscape

6. Octreotide (somatostatin analogue)
   Purpose: sometimes used for PLE with lymphangiectasia; may reduce lymph flow and protein loss. Side effects: gallstones, glucose changes. (Evidence from non-CDG PLE reports; case-by-case specialist use.) Wiley Online Library+1

7. Ursodeoxycholic acid
   Purpose: cholestasis support if present. Mechanism: improves bile flow, protects hepatocytes. Side effects: GI upset. (General hepatology measure.)

8. Fat-soluble vitamins A, D, E, K (pharmacy-grade)
   Purpose: replace malabsorption losses. Mechanism: restores vitamin levels; vitamin K supports coagulation. Side effects: toxicity if overdosed—lab-guided. UVA School of Medicine

9. Vitamin K (phytonadione)
   Purpose: correct vitamin K–responsive coagulopathy. Mechanism: cofactor for clotting factor γ-carboxylation. Side effects: injection reactions.

10. Albumin infusion (+ loop/thiazide diuretics as needed)
    Purpose: treat severe edema/ascites from low albumin. Mechanism: raises oncotic pressure; diuretics remove excess fluid. Side effects: fluid shifts, electrolyte changes. UVA School of Medicine

11. Spironolactone / Furosemide
    Purpose: edema/ascites control with albumin strategy. Mechanism: natriuresis; potassium-sparing or loop diuresis. Side effects: electrolyte abnormalities.

12. Proton-pump inhibitor (e.g., omeprazole)
    Purpose: reflux/vomiting relief to protect nutrition. Mechanism: reduces gastric acid. Side effects: GI infections risk with long use.

13. Antimotility agent (e.g., loperamide)
    Purpose: symptomatic diarrhea control (specialist oversight in pediatrics). Mechanism: slows intestinal transit. Side effects: constipation, rare ileus.

14. Antibiotics for bacterial overgrowth (e.g., rifaximin)
    Purpose: select cases with SIBO-like symptoms. Mechanism: reduces intraluminal bacteria. Side effects: GI upset.

15. IVIG (intravenous/subcutaneous immunoglobulin)
    Purpose: recurrent infections with low IgG from PLE. Mechanism: passive antibody replacement. Side effects: headache, aseptic meningitis, thrombosis risk in predisposed patients. PMC+1

16. Low-molecular-weight heparin (LMWH) (specialist-directed only)
    Purpose: treat or prevent thrombosis in high-risk settings. Mechanism: anti-Xa anticoagulation; balance against bleeding risk with abnormal factors. Side effects: bleeding. PubMed

17. Antithrombin (AT) concentrate (selected cases)
    Purpose: correct severe AT deficiency to enable heparin activity if required. Mechanism: restores AT levels. Side effects: infusion reactions. BioMed Central

18. Beta-blockers (e.g., propranolol) or antiarrhythmics
    Purpose: manage rhythm problems when present. Mechanism: stabilize cardiac conduction. Side effects: bradycardia, hypotension. Frontiers in Glycosylation

19. ACE inhibitor (e.g., enalapril)
    Purpose: cardiac function support if cardiomyopathy. Mechanism: reduces afterload and remodeling. Side effects: cough, hyperkalemia.

20. Acetazolamide (off-label in some CDG for episodic ataxia)
    Purpose: reduce attacks of ataxia in selected patients. Mechanism: carbonic anhydrase inhibition alters neuronal excitability. Side effects: paresthesias, kidney stones. (Reported in CDG community summaries; clinician-directed.) CDG Care

Key reality check: Unlike a few CDGs (e.g., MPI-CDG with mannose, PGM1-CDG with galactose), ALG8-CDG currently has no proven substrate or vitamin therapy; care is supportive. MDPI

---

Dietary molecular supplements

All supplementation should be lab-guided and supervised.

1. MCT oil: calories that bypass lymphatics; supports growth in PLE. UVA School of Medicine

2. Whey or elemental protein: easier protein delivery; rebuilds albumin and muscle. UVA School of Medicine

3. Vitamin A: supports vision/epithelium if low; fat-soluble, avoid overdose. UVA School of Medicine

4. Vitamin D + Calcium: bone health in limited mobility and steroid exposure. UVA School of Medicine

5. Vitamin E: antioxidant; deficiency common in fat malabsorption. UVA School of Medicine

6. Vitamin K: supports clotting when levels are low. UVA School of Medicine

7. Iron: correct iron-deficiency anemia from chronic disease or losses.

8. Zinc: epithelial repair/diarrhea reduction in deficiency.

9. Folate/B12: correct megaloblastic anemia if present.

10. Probiotics (careful selection): may reduce diarrhea in some children; avoid in immunocompromised states.

---

Immunity booster / regenerative / stem-cell” drugs

There are no approved immune-booster or stem-cell therapies for ALG8-CDG. Below are supportive or investigational strategies your team might discuss—not endorsements:

1. IVIG/SCIG for secondary hypogammaglobulinemia from PLE to reduce infections. PMC

2. Palivizumab (seasonal RSV monoclonal) in selected high-risk infants to prevent severe RSV (general pediatric criteria apply).

3. Nutritional “immune support” via adequate protein, micronutrients, and vitamin D—foundational, not “booster pills.” UVA School of Medicine

4. Clinical-trial enrollment (future gene therapy or small-molecule chaperones if developed). Families often connect via CDG registries. Frontiers

5. Hematopoietic stem-cell transplant: not established for ALG8-CDG (used rarely in other disorders for different mechanisms).

6. Organ transplantation: liver/heart transplants have roles in a few other CDGs (e.g., MPI-CDG, DOLK-CDG), not standard for ALG8-CDG. MDPI

---

Surgeries

1. Cataract extraction (early in infancy if visually significant)
   Why: to prevent permanent vision loss (amblyopia) and improve function. Medscape+1

2. Achilles tenotomy within the Ponseti pathway for clubfoot
   Why: small procedure to complete correction after casting; improves standing/walking. Hospital for Special Surgery

3. Gastrostomy tube placement (± Nissen fundoplication)
   Why: secure nutrition, protect lungs in severe reflux/aspiration.

4. Cardiac device or defect repair (selected cases)
   Why: treat rhythm problems or structural lesions documented in some ALG8-CDG patients. Frontiers in Glycosylation

5. Hernia repair or other supportive surgeries
   Why: symptom relief and prevention of complications if present.

---

Prevention tips

1. Early diagnosis and regular follow-up in a metabolic center. CDG Hub

2. Nutrition plan (high-protein, MCT when indicated) to prevent PLE-related complications. UVA School of Medicine

3. Vaccinations and infection-prevention habits at home/school.

4. Hydration and mobility to reduce clot risk during illness or travel. PubMed

5. Peri-procedure hemostasis plans before surgery or dental work. Wiley Online Library

6. Eye checks to catch and treat cataracts/strabismus early. PubMed

7. Cardiac monitoring if symptoms suggest rhythm or structural issues. Frontiers in Glycosylation

8. Avoid hepatotoxic or sedating drugs unless necessary and monitored.

9. Emergency plan (seizure rescue plan; dehydration/diarrhea action plan).

10. Genetic counseling for family planning. CDG Hub

---

When to see a doctor urgently

• New or worsening seizures, loss of consciousness, or severe headache.

• Rapid swelling, shortness of breath, or big weight gain over days (possible fluid overload).

• Bloody stools, black stools, unusual bruising, or prolonged bleeding.

• Fever, persistent vomiting/diarrhea, or signs of dehydration (dry mouth, reduced urine).

• Jaundice, increasing belly size (ascites), or severe pain.

• Any sudden change in vision, heart rhythm, or behavior.

---

What to eat & what to avoid

Eat more of (as guided by your dietitian):

1. Protein-rich foods at each meal (eggs, fish, lean meats, pulses, tofu).

2. MCT-enriched formulas/oils if lymphatic gut loss is suspected. UVA School of Medicine

3. Small, frequent meals to maintain energy and reduce GI stress.

4. Oral rehydration solutions during diarrhea to maintain fluids/electrolytes.

5. Fruits/veggies for vitamins; fortified products when needed.

6. Vitamin/mineral supplements only as prescribed (A, D, E, K, iron, zinc, folate/B12). UVA School of Medicine

Limit/avoid:

7. Large loads of long-chain fats if lymphangiectasia/PLE is present (favor MCTs instead). UVA School of Medicine

8. High-salt ultra-processed foods when edema is an issue.

9. Alcohol (older teens/adults) and unregulated herbal products that may harm the liver.

10. Grapefruit or other interactions if the care team warns of drug–food issues.

---

FAQs

1) Is CDG-Ih curable?
Not yet. There is no approved disease-specific therapy for ALG8-CDG; care is supportive and complication-focused. Research is ongoing. CDG Hub+1

2) How is it confirmed?
By genetic testing showing ALG8 variants, usually after transferrin isoform analysis suggests a type-I CDG. CDG Hub

3) What symptoms are most common?
Hypotonia, diarrhea/PLE, liver disease, coagulopathy, developmental delay; eye and heart issues can occur. PubMed

4) Why is there swelling?
PLE causes loss of albumin and antibodies into the gut; low albumin leads to edema/ascites. UVA School of Medicine

5) Can seizures be treated?
Yes—antiepileptic medicines like levetiracetam are commonly used; some cases benefit from a ketogenic diet under specialist care. HSSiEM+1

6) Why are clots and bleeding both a risk?
Many clotting and anti-clotting proteins are glycoproteins; under-glycosylation can lower several factors on both sides, creating a mixed risk. Wiley Online Library

7) Are there diets that fix the disease?
No diet cures CDG-Ih, but high-protein and MCT-based plans often help growth and edema in PLE. UVA School of Medicine

8) Is octreotide or budesonide a standard treatment?
They’re not standard for ALG8-CDG, but specialists sometimes trial them in severe, refractory PLE, based on evidence from other PLE conditions. Wiley Online Library+1

9) Can vision be helped?
Yes. Early cataract surgery (when needed) and strabismus care can improve visual outcomes. Medscape

10) What about heart problems?
If present, they’re managed per cardiology guidelines (medicines, monitoring, rarely devices). Frontiers in Glycosylation

11) Will my child outgrow this?
No, it’s genetic and lifelong, but severity varies; some individuals have milder, stable courses. Nature

12) Are there clinical trials?
CDG groups and registries track research; ask your team about trial eligibility and natural-history studies. Frontiers

13) What specialists do we need?
Metabolic genetics, gastro/hepatology, hematology, neurology, cardiology, ophthalmology, orthopedics, nutrition, therapies—often coordinated in a multidisciplinary clinic. Metabolic Support UK

14) How often should labs be checked?
Typically every 3–6 months (or sooner if symptoms) for nutrition, liver, coagulation, and immunoglobulins—your team will set a schedule.

15) What is the outlook?
Outcomes vary widely. Early recognition, strong nutrition, seizure control, and proactive prevention of bleeding/clots and infections improve quality of life. Cohorts show both severe early presentations and individuals with longer-term, milder courses. Nature

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 12, 2025.